Composition and stage dynamics of mitochondrial complexes in<em> Plasmodium falciparum</em> (Publications)
organisms, which only represent a fraction of eukaryotic diversity. The unusual mitochondrion of malaria parasites is a validated drug target but remains poorly understood. Here, we apply complexome profiling
Design, synthesis, and evaluation of 5'-diphenyl nucleoside analogues as inhibitors of the <em>Plasmodium falciparum</em> dUTPase (Publications)
Deoxyuridine 5'-triphosphate nucleotidohydrolase (dUTPase) is a potential drug target for malaria. We previously reported some 5'-tritylated deoxyuridine analogues (both cyclic and acyclic) as selective
Immunoglobulin kappa light-chain V, J, and C gene sequences of the owl monkey <em>Aotus nancymaae</em> (Publications)
supports the proposal to use the Aotus Plasmodium falciparum infection model for the evaluation of malaria vaccine candidates
Vector-borne diseases in humans and animals: activities of the Swiss Tropical Institut and risks for Switzerland (Publications)
This overview presents the Swiss Tropical Institute's (STI) activities on vector-borne diseases (malaria, trypanosomosis, and leishmaniosis in humans and tick-borne diseases in livestock), describes the
Trypanocidal activity of diarylheptanoids from <em>Schrankia leptocarpa</em> DC (Publications)
Schrankia leptocara is a medicinal species use traditionally in Benin to treat malaria. A previous study showed interesting antimalarial activity against two strains of Plasmodium falciparum. Phytochemical
Structure-activity relationship studies of pyrrolone antimalarial agents (Publications)
mammalian (L6) cells. Three representative compounds were selected for evaluation in a rodent model of malaria infection, and the best compound showed improved ability to decrease parasitaemia and a slight increase
Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a softfocus kinase library: part 2 (Publications)
for antiplasmodial activity against NF54 (sensitive) and K1 (multidrug resistant) strains of the malaria parasite Plasmodium falciparum and evaluated for both aqueous solubility and metabolic stability
Costs and cost-effectiveness of <em>Plasmodium vivax </em>control (Publications)
The continued success of efforts to reduce the global malaria burden will require sustained funding for interventions specifically targeting Plasmodium vivax The optimal use of limited financial resources
Declining burden of <em>Plasmodium vivax</em> in a population in northwestern Thailand from 1995 to 2016 before comprehensive primaquine prescription... (Publications)
and artemisinin-based therapy, species-specific diagnostics, and bed net usage all of which reduce malaria transmission but not P. vivax relapse. In the absence of widespread primaquine use for radical cure
Validation of the protein kinase <em>Pf</em>CLK3 as a multistage cross-species malarial drug target (Publications)
target for drugs, with the potential to offer a cure-to be prophylactic and transmission blocking in malaria.